LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
$2.45
株価 · 8月 19, 2026
ファンダメンタルズ（時点） 8月 6, 2026
52週レンジ
$1–$3
86% of range
アナリスト評価
BUY
11 analysts
目標株価
$4
+58% upside
P/E (TTM)
-17.5
ROE
-39.7%
純利益率
-101.1%
Lexicon Pharmaceuticals, Inc. - Common Stock について Wikipediaからの企業概要
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
続きを読む
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of diffrent compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
LXRX 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$2.44
時価総額
$894M
P/E (TTM)
-17.5
EPS（TTM）
$-0.14
収益（TTM）
$50M
配当利回り
—
ROE
-39.7%
負債/自己資本
0.5
52週レンジ
$1 – $3
LXRX 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
Configure
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益と純利益
$50M
2016-12-31
→
2025-12-31
EPS
$-0.14
2017-12-31
→
2025-12-31
フリーキャッシュフロー
$-68M
2016-12-31
→
2025-12-31
利益率
-101.1%
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
指標
5年トレンド
LXRX
競合中央値
P/E (TTM)
-17.5
29.9
P/S (TTM) (株価売上高倍率（TTM）)
18.0
14.4
P/B (株価純資産倍率)
8.3
4.4
EV / EBITDA (EV/EBITDA)
-17.6
—
Price / FCF (株価FCF倍率)
-13.2
—
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
指標
5年トレンド
LXRX
競合中央値
Operating Margin (営業利益率)
-98.2%
—
Net Profit Margin (純利益率)
-101.1%
0.70%
ROA
-20.8%
-0.55%
ROE
-39.7%
-2.5%
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
指標
5年トレンド
LXRX
競合中央値
Debt / Equity (負債資本倍率)
0.5
—
Current Ratio (流動比率)
4.9
3.9
Quick Ratio (クイックレシオ)
4.7
—
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
指標
5年トレンド
LXRX
競合中央値
Revenue YoY (収益（前年比）)
60.2%
—
Revenue CAGR 3Y (収益（3年CAGR）)
610.2%
—
Revenue CAGR 5Y (収益（5年CAGR）)
15.7%
—
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
指標
5年トレンド
LXRX
競合中央値
LXRX アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
買い
11 アナリスト
- 強い買い 3 27.3%
- 買い 5 45.5%
- 保有 3 27.3%
- 売り 0 0.0%
- 強い売り 0 0.0%
12ヶ月目標株価
5 アナリスト · 2026-08-19
中央値
$3.10
平均値
$3.86
現在
$2.44
安値
$2.00
高値
$6.00
中央値ターゲット
$3.10
+26.8%
平均値ターゲット
$3.86
+57.7%
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
0.03%
| 期間 | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|
| 2026年6月30日 | $-0.07 | $-0.05 | -0.02% |
| 2026年3月31日 | $0.00 | $-0.04 | 0.04% |
| 2025年12月31日 | $-0.04 | $-0.07 | 0.03% |
| 2025年9月30日 | $-0.04 | $-0.07 | 0.03% |
| 2025年6月30日 | $0.01 | $-0.08 | 0.09% |
| 2025年3月31日 | $-0.07 | $-0.10 | 0.03% |
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| SPTX | — | — | — | — | — | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | — |
| SGP | — | — | — | — | 50.0% | — |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書 16
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
貸借対照表 30
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
キャッシュフロー 17
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
収益性 7
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
流動性と支払能力 5
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
効率性 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
成長率 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM） 14
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
損益計算書 14
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | -725,713,000 | 363,399,000 | 363,294,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | -307,937,000 | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | -725,989,000 | 363,399,000 | 363,570,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | 7,749,000 | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | $-26M | · | $-64M | $-55M | $-45M | · | $-50M | $-44M | $-31M | · | $-23M |
貸借対照表 28
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | $101M | · | $100M | $99M | $100M | · | $99M | $99M | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
キャッシュフロー 14
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | $-22M | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
収益性 5
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | -2034.8% | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | -13955.8% | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | -2004.4% | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | -14165.3% | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | -2020.8% | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | -13955.8% | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | -7.1% | · | -21.7% | -15.5% | -16.7% | · | -21.6% | -20.9% | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | -12.3% | · | -40.8% | -25.1% | -25.7% | · | -35.6% | -34.9% | -35.3% | · | -16.7% |
流動性と支払能力 5
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | 2.2 | · | 7.5 | 11.5 | 15.6 | · | 6.9 | 10.1 | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | 2.2 | · | 7.2 | 11.2 | 15.3 | · | 6.8 | 9.9 | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.8 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.5 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | -22.6 | -17.1 | · | -26.7 |
効率性 3
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | 0.4 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | 0.1 | · | 1.1 | 1.0 | 1.3 | · | 0.9 | 0.9 | · | · | · |
バリュエーション（TTM） 12
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65M | $65M | · | $46M | $34M | $6M | · | $5M | $3M | $2M | · | $542.0K | $415.0K | · | · | · | |
| Net Income TTM | $-42M | $-36M | · | $-100M | $-140M | $-192M | · | $-217M | $-197M | $-176M | · | $-151M | $-125M | $-103M | · | $-95M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -24.0 | -15.6 | · | -4.8 | -2.3 | -0.7 | · | -2.1 | -2.1 | -3.0 | · | -1.5 | · | · | · | · | |
| P/S | 16.5 | 10.2 | · | 10.7 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -35.2 | -613.0 | · | -35.6 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 14.4 | 8.3 | · | 9.4 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.2% | -6.4% | · | -20.7% | -43.2% | -134.8% | · | -48.4% | -47.6% | -33.3% | · | -67.0% | · | · | · | · |
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
損益計算書
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 収益 | $50M | $31M | $1M | $139.0K | $298.0K |
| 営業利益率 % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| 純利益 | $-50M | $-200M | $-177M | $-102M | $-88M |
| 希薄化後EPS | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
貸借対照表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 負債資本倍率 | 0.5 | 0.7 | 1.1 | — | 0.0 |
| 流動比率 | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| クイックレシオ | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
キャッシュフロー
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-68M | $-180M | $-162M | $-90M | $-88M |
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
📊
あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
機関投資家（13F） 169 提出者 · $760.9M合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 48 (+14 前期比) | 27 (+14 前期比) | 34 (-11 前期比) | 37 (+17 前期比) | +25.0M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| Artal Group S.A. | $420,374,549 | 175,156,062 | 55.25% | 株式数 |
| Siren, L.L.C. | $106,328,443 | 44,303,518 | 13.97% | 株式数 |
| FMR LLC | $65,057,059 | 27,107,108 | 8.55% | 株式数 |
| Sessa Capital IM, L.P. | $45,506,006 | 18,960,836 | 5.98% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $23,762,899 | 9,901,208 | 3.12% | 株式数 |
| Point72 Asset Management, L.P. | $19,803,180 | 8,251,325 | 2.60% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $12,946,507 | 5,393,025 | 1.70% | 株式数 |
| STATE STREET CORP | $11,802,646 | 4,917,769 | 1.55% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5,658,598 | 2,357,749 | 0.74% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4,696,260 | 1,956,775 | 0.62% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $3,922,970 | 1,634,571 | 0.52% | 株式数 |
| CIBC Private Wealth Group LLC | $3,240,347 | 2,400,257 | 0.43% | 株式数 |
| Ishara Investments LP | $3,050,400 | 1,271,000 | 0.40% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $2,722,150 | 1,134,229 | 0.36% | 株式数 |
| RENAISSANCE TECHNOLOGIES LLC | $2,704,800 | 1,127,000 | 0.36% | 株式数 |
| MACKENZIE FINANCIAL CORP | $2,312,050 | 963,354 | 0.30% | 株式数 |
| ADAR1 Capital Management, LLC | $1,800,000 | 750,000 | 0.24% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,604,400 | 668,500 | 0.21% | コールオプション |
| TWO SIGMA INVESTMENTS, LP | $1,544,266 | 643,444 | 0.20% | 株式数 |
| JANE STREET GROUP, LLC | $1,398,960 | 582,900 | 0.18% | コールオプション |
| CITADEL ADVISORS LLC | $1,348,733 | 561,972 | 0.18% | 株式数 |
| VANGUARD GROUP INC | $1,277,587 | 1,110,945 | 0.17% | 株式数 |
| Compagnie Lombard Odier SCmA | $1,152,000 | 480,000 | 0.15% | 株式数 |
| BARCLAYS PLC | $890,636 | 371,098 | 0.12% | 株式数 |
| CITADEL ADVISORS LLC | $886,320 | 369,300 | 0.12% | コールオプション |
| XTX Topco Ltd | $858,905 | 357,877 | 0.11% | 株式数 |
| GOLDMAN SACHS GROUP INC | $725,810 | 302,421 | 0.10% | 株式数 |
| CANADA PENSION PLAN INVESTMENT BOARD | $618,960 | 257,900 | 0.08% | 株式数 |
| RHUMBLINE ADVISERS | $616,523 | 256,885 | 0.08% | 株式数 |
| WELLS FARGO & COMPANY/MN | $544,865 | 227,027 | 0.07% | 株式数 |
| GROUP ONE TRADING LLC | $420,031 | 175,013 | 0.06% | 株式数 |
| Virtus Investment Advisers, LLC | $408,996 | 170,415 | 0.05% | 株式数 |
| Headlands Technologies LLC | $401,275 | 167,198 | 0.05% | 株式数 |
| Ikarian Capital, LLC | $395,218 | 164,674 | 0.05% | 株式数 |
| CITIGROUP INC | $386,021 | 160,842 | 0.05% | 株式数 |
| Quarry LP | $374,846 | 156,186 | 0.05% | 株式数 |
| MetLife Investment Management, LLC | $351,384 | 146,410 | 0.05% | 株式数 |
| Bank of New York Mellon Corp | $345,307 | 143,878 | 0.05% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $344,321 | 143,467 | 0.05% | 株式数 |
| PANAGORA ASSET MANAGEMENT INC | $316,901 | 132,042 | 0.04% | 株式数 |
| State of Wyoming | $285,816 | 119,090 | 0.04% | 株式数 |
| BlackRock, Inc. | $284,436 | 118,515 | 0.04% | 株式数 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $273,874 | 114,114 | 0.04% | 株式数 |
| Cornerstone Investment Partners, LLC | $272,974 | 113,739 | 0.04% | 株式数 |
| Invesco Ltd. | $238,190 | 99,246 | 0.03% | 株式数 |
| ALGERT GLOBAL LLC | $221,160 | 92,150 | 0.03% | 株式数 |
| TWO SIGMA ADVISERS, LP | $208,124 | 180,977 | 0.03% | 株式数 |
| BANK OF NOVA SCOTIA | $207,857 | 86,607 | 0.03% | 株式数 |
| LPL Financial LLC | $203,799 | 84,916 | 0.03% | 株式数 |
| Vanguard Global Advisers, LLC | $187,070 | 77,946 | 0.02% | 株式数 |
| AQR CAPITAL MANAGEMENT LLC | $180,101 | 75,042 | 0.02% | 株式数 |
| Police & Firemen's Retirement System of New Jersey | $176,165 | 73,402 | 0.02% | 株式数 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | $171,426 | 71,427 | 0.02% | 株式数 |
| PRUDENTIAL FINANCIAL INC | $171,228 | 71,345 | 0.02% | 株式数 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $167,393 | 69,747 | 0.02% | 株式数 |
| NEW YORK STATE COMMON RETIREMENT FUND | $164,160 | 68,400 | 0.02% | 株式数 |
| TWO SIGMA SECURITIES, LLC | $159,300 | 66,375 | 0.02% | 株式数 |
| SEI INVESTMENTS CO | $153,449 | 63,937 | 0.02% | 株式数 |
| Nuveen, LLC | $153,449 | 63,937 | 0.02% | 株式数 |
| Straight Path Wealth Management | $150,398 | 62,666 | 0.02% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $144,000 | 60,000 | 0.02% | 株式数 |
| R Squared Ltd | $131,964 | 54,985 | 0.02% | 株式数 |
| Vanguard Personalized Indexing Management, LLC | $130,402 | 54,334 | 0.02% | 株式数 |
| Fortis Group Advisors, LLC | $120,000 | 50,000 | 0.02% | 株式数 |
| Schonfeld Strategic Advisors LLC | $118,642 | 49,435 | 0.02% | 株式数 |
| SCOTIA CAPITAL INC. | $117,291 | 48,871 | 0.02% | 株式数 |
| PROFUND ADVISORS LLC | $116,606 | 48,586 | 0.02% | 株式数 |
| VOYA INVESTMENT MANAGEMENT LLC | $114,650 | 47,771 | 0.02% | 株式数 |
| AXQ CAPITAL, LP | $109,745 | 45,727 | 0.01% | 株式数 |
| BOOTHBAY FUND MANAGEMENT, LLC | $106,356 | 44,315 | 0.01% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $105,768 | 67,800 | 0.01% | 株式数 |
| WINTON GROUP Ltd | $103,680 | 43,200 | 0.01% | 株式数 |
| INTECH INVESTMENT MANAGEMENT LLC | $101,978 | 42,491 | 0.01% | 株式数 |
| LMR Partners LLP | $98,618 | 41,091 | 0.01% | 株式数 |
| BANK OF MONTREAL /CAN/ | $96,000 | 40,000 | 0.01% | 株式数 |
| NORTHERN TRUST CORP | $93,794 | 39,081 | 0.01% | 株式数 |
| BNP PARIBAS FINANCIAL MARKETS | $90,672 | 37,780 | 0.01% | 株式数 |
| Cubist Systematic Strategies, LLC | $85,704 | 63,484 | 0.01% | 株式数 |
| Rafferty Asset Management, LLC | $81,816 | 34,090 | 0.01% | 株式数 |
| ProShare Advisors LLC | $78,212 | 32,588 | 0.01% | 株式数 |
| Leonteq Securities AG | $72,000 | 30,000 | 0.01% | 株式数 |
| PINNACLE ASSOCIATES LTD | $69,636 | 29,015 | 0.01% | 株式数 |
| VICTORY CAPITAL MANAGEMENT INC | $58,135 | 24,223 | 0.01% | 株式数 |
| Legal & General Group Plc | $58,044 | 24,185 | 0.01% | 株式数 |
| XPONANCE LLC | $57,031 | 23,763 | 0.01% | 株式数 |
| Graham Capital Management, L.P. | $56,498 | 23,541 | 0.01% | 株式数 |
| D. E. Shaw & Co., Inc. | $53,280 | 22,200 | 0.01% | 株式数 |
| Quadrature Capital Ltd | $52,795 | 21,998 | 0.01% | 株式数 |
| Invera Wealth Advisors, LLC | $48,000 | 20,000 | 0.01% | 株式数 |
| DIKER MANAGEMENT LLC | $48,000 | 20,000 | 0.01% | 株式数 |
| TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | $48,000 | 20,000 | 0.01% | 株式数 |
| Russell Investments Group, Ltd. | $47,764 | 19,902 | 0.01% | 株式数 |
| Point72 Asia (Singapore) Pte. Ltd. | $47,282 | 35,024 | 0.01% | 株式数 |
| Tower Research Capital LLC (TRC) | $46,764 | 19,485 | 0.01% | 株式数 |
| KWB Wealth | $46,736 | 40,640 | 0.01% | 株式数 |
| SBI Securities Co., Ltd. | $46,092 | 19,205 | 0.01% | 株式数 |
| PRINCIPAL FINANCIAL GROUP INC | $45,682 | 19,034 | 0.01% | 株式数 |
| CREDIT AGRICOLE S A | $45,540 | 18,975 | 0.01% | 株式数 |
| WOLVERINE TRADING, LLC | $43,785 | 31,500 | 0.01% | プットオプション |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $42,960 | 17,900 | 0.01% | プットオプション |
企業インサイダー 49 人のインサイダー · 32人の役員 · 19人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 2026年2月28日 M | 298,432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 2024年2月28日 M | 1,098,068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 2014年2月28日 M | 1,021,329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 2026年2月28日 M | 105,356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2009年6月2日 A | — | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 2008年2月7日 A | 50,200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 2024年7月8日 A | 324,214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 2026年2月28日 M | 31,264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 2026年2月28日 M | 150,132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 2026年2月28日 M | 277,945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 2026年2月28日 M | 323,430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 2026年2月28日 M | 93,869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 2026年2月28日 M | 428,802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 2025年2月28日 M | 76,368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 2025年2月28日 M | 339,104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 2025年2月13日 A | — | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 2024年2月28日 M | 162,672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 2024年2月8日 A | — | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 2023年2月28日 M | 53,136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 2021年3月15日 M | 71,766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 2020年4月22日 F | 55,584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 2020年4月22日 F | 85,719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2015年3月2日 M | 8,235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 2014年2月28日 M | 278,703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 2010年2月15日 A | — | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 2010年2月15日 A | 27,306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 2008年2月7日 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 2008年2月7日 A | 10,200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 2008年2月7日 A | — | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 2007年2月13日 A | — | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 2004年2月23日 M | 15,000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 2004年1月12日 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | 取締役 | 2026年6月3日 M | 89,312 | 0 | 0 | $0 |
| Diane E. Sullivan | 取締役 | 2026年6月3日 M | 126,122 | 0 | 0 | $0 |
| Judith L Swain | 取締役 | 2026年6月3日 M | 174,486 | 0 | 0 | $0 |
| Amouyal Philippe | 取締役 | 2026年6月3日 M | 374,486 | 0 | 0 | $0 |
| Sam L Barker | 取締役 | 2026年6月3日 M | 213,771 | 0 | 0 | $0 |
| Christopher J Sobecki | 取締役 | 2026年6月3日 M | 293,177 | 0 | 0 | $0 |
| Raymond Debbane | 取締役 | 2026年6月3日 M | 1,995,498 | 7 | 0 | $723,048 |
| Robert J Lefkowitz MD | 取締役 | 2024年5月13日 A | 48,364 | 0 | 0 | $0 |
| Frank Palantoni | 取締役 | 2023年5月21日 M | 40,332 | 0 | 0 | $0 |
| Alan S Nies | 取締役 | 2023年5月21日 M | 41,046 | 0 | 0 | $0 |
| Invus C.V. | 取締役 | 2020年12月31日 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | 取締役 | 2009年4月24日 A | — | 0 | 0 | $0 |
| Clayton Stuart Rose | 取締役 | 2007年6月26日 P | 25,000 | 0 | 0 | $0 |
| Barry Mills | 取締役 | 2007年4月26日 A | 25,000 | 0 | 0 | $0 |
| Patricia M Cloherty | 取締役 | 2006年4月27日 A | — | 0 | 0 | $0 |
| Thomas C Caskey | 取締役 | 2005年10月13日 P | 6,300 | 0 | 0 | $0 |
| Praveen Tyle | — | 2021年2月28日 M | 120,791 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
アクティビストおよび5%超のオーナー 11保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 提出書類 | 2026年5月8日 | 39.40% | 修正 | — | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 提出書類 | 2024年12月9日 | — | 初回提出 | — | SEC |
| 2012年2月24日 | — | 初回提出 | — | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 2011年12月27日 | — | 初回提出 | — | SEC |
| 2011年11月14日 | — | 初回提出 | — | SEC | |
| 2011年8月15日 | — | 初回提出 | — | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 2010年3月19日 | — | 初回提出 | 資本構成 | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 提出書類 | 2005年8月5日 | — | 初回提出 | — | SEC |
| 未開示の報告者, 未開示の報告者, 未開示の報告者 | 2003年8月8日 | — | 初回提出 | — | SEC |
| 未開示の報告者, 未開示の報告者, 未開示の報告者 | 2003年7月18日 | — | 初回提出 | 受動的投資 | SEC |
| 未開示の報告者, 未開示の報告者, 未開示の報告者, 未開示の報告者 | 2003年3月19日 | — | 初回提出 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF保有状況 14のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 1,032,223 NS | 2026年5月31日 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 110,085 NS | 2026年5月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 日次 |
| IWV · iShares Trust | — | — | 2026年8月18日 | 日次 |
| IWO · iShares Trust | — | — | 2026年8月18日 | 日次 |
| IWM · iShares Trust | — | — | 2026年8月18日 | 日次 |
| IWC · iShares Trust | — | — | 2026年8月18日 | 日次 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026年7月13日 | 日次 |
| VHT · VANGUARD WORLD FUND | — | — | 2026年7月20日 | 日次 |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 2026年8月5日 | 日次 |